Intrust Bank NA Raises Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Intrust Bank NA raised its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 12.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,439 shares of the biotechnology company’s stock after purchasing an additional 382 shares during the period. Intrust Bank NA’s holdings in Blueprint Medicines were worth $300,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in BPMC. Pictet Asset Management Holding SA increased its position in shares of Blueprint Medicines by 1.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,183,682 shares of the biotechnology company’s stock worth $103,241,000 after purchasing an additional 17,175 shares in the last quarter. Norges Bank purchased a new stake in Blueprint Medicines in the fourth quarter valued at about $62,028,000. BIT Capital GmbH boosted its holdings in Blueprint Medicines by 4.4% in the fourth quarter. BIT Capital GmbH now owns 78,921 shares of the biotechnology company’s stock worth $6,883,000 after acquiring an additional 3,347 shares in the last quarter. EFG Asset Management North America Corp. grew its position in Blueprint Medicines by 120.5% during the 4th quarter. EFG Asset Management North America Corp. now owns 74,300 shares of the biotechnology company’s stock worth $6,477,000 after purchasing an additional 40,611 shares during the last quarter. Finally, Prudential Financial Inc. increased its position in shares of Blueprint Medicines by 11.9% in the 4th quarter. Prudential Financial Inc. now owns 100,538 shares of the biotechnology company’s stock valued at $8,769,000 after acquiring an additional 10,687 shares during the period.

Insider Buying and Selling

In related news, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the sale, the insider now owns 14,967 shares of the company’s stock, valued at approximately $1,496,700. This represents a 13.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $102.28, for a total transaction of $511,400.00. Following the completion of the transaction, the director now directly owns 157,557 shares in the company, valued at $16,114,929.96. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,608 shares of company stock worth $3,319,587. 4.21% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BPMC has been the subject of a number of research reports. Morgan Stanley began coverage on Blueprint Medicines in a research report on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price target for the company. Piper Sandler upped their target price on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Wedbush reiterated an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. JPMorgan Chase & Co. lifted their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, Wolfe Research initiated coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines currently has a consensus rating of “Moderate Buy” and an average target price of $124.95.

Blueprint Medicines Stock Down 1.1 %

Shares of NASDAQ BPMC opened at $88.72 on Monday. The firm has a market cap of $5.67 billion, a price-to-earnings ratio of -82.15 and a beta of 0.58. The company’s 50-day simple moving average is $98.13 and its 200-day simple moving average is $94.04. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 52-week low of $80.68 and a 52-week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.